Factors associated with refractory renal disease in patients with systemiclupus erythematosus: The role of patient nonadherence

Citation
In. Bruce et al., Factors associated with refractory renal disease in patients with systemiclupus erythematosus: The role of patient nonadherence, ARTH C RES, 13(6), 2000, pp. 406-408
Citations number
6
Categorie Soggetti
Rheumatology
Journal title
ARTHRITIS CARE AND RESEARCH
ISSN journal
08937524 → ACNP
Volume
13
Issue
6
Year of publication
2000
Pages
406 - 408
Database
ISI
SICI code
0893-7524(200012)13:6<406:FAWRRD>2.0.ZU;2-S
Abstract
Objective. To assess the prevalence and underlying reasons for the developm ent of chronic renal insufficiency (CRI) in patients with systemic lupus er ythematosus (SLE) seen over a 3-year period in our lupus clinic, in particu lar to determine the frequency and types of patient-dependent factors that were associated with nonadherence when it occurred. Methods. We determined the frequency and types of patient-dependent factors that were associated with the development of CRI in patients with SLE. CRI was defined as a serum creatinine level greater than or equal to 200 mu mo l/l for at least 6 months. Results. Of the 462 patients followed at the lupus clinic between 1995 and 1998, 17 patients developed CRI Patient-related factors were deemed to be t he major reason for the development of CRI in 5 of these. Three of the 5 pa tients were nonwhite, and the patients who were white were new immigrants. All 5 patients were reluctant to take high-dose corticosteroids because of potential adverse effects. Financial problems contributed to nonadherence i n 2 cases. Two patients refused to continue steroids and immunosuppressive therapy and chose to use "alternative" medications as their sole therapy. O f these 5 patients, 3 are now on long-term renal replacement therapy, I has died, and 1 patient continues to be followed with a serum creatinine level of 250 mu mol/l. Conclusion. There is a need for an educational program based on patients' c ultural background in order to enhance patients' understanding of the aims, risks, and benefits of therapy in SLE.